BCM
TNGX icon

Bridgeway Capital Management’s Tango Therapeutics TNGX Stock Holding History

Bridgeway Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$293K Sell
14,000
-7,500
-35% -$104K 0.01% 940
2025
Q4 		$190K Hold
21,500
– – ﹤0.01% 1028
2025
Q3 		$181K Sell
21,500
-103,500
-83% -$700K ﹤0.01% 1031
2025
Q2 		$640K Hold
125,000
– – 0.02% 729
2025
Q1 		$171K Buy
+125,000
New +$307K ﹤0.01% 951

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Bridgeway Capital Management's TNGX Position: Q1 2026 in Review

Bridgeway Capital Management reduced its Tango Therapeutics (TNGX) stake by 35% in Q1 2026, selling an estimated $104K and leaving 14,000 shares worth $293K. The position accounts for 0.01% of the portfolio, ranked #940.

Bridgeway Capital Management first reported a position in TNGX in Q1 2025 and has held it in 5 quarters since. The position peaked at $640K in Q2 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Bridgeway Capital Management held 14,000 shares of Tango Therapeutics worth $293K as of Q1 2026.
  • Bridgeway Capital Management sold 7,500 Tango Therapeutics shares in Q1 2026, an estimated $104K.
  • Tango Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #940 holding.
  • Bridgeway Capital Management first reported a position in Tango Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Bridgeway Capital Management's Tango Therapeutics position peaked at $640K in Q2 2025.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.